
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX – Free Report) – Research analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Aldeyra Therapeutics in a research note issued on Tuesday, November 10th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will post earnings per share of ($0.27) for the year, up from their previous estimate of ($0.39). HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.10) EPS, FY2028 earnings at $0.01 EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $0.29 EPS.
Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05.
View Our Latest Analysis on Aldeyra Therapeutics
Aldeyra Therapeutics Trading Up 2.2%
Shares of NASDAQ:ALDX opened at $0.64 on Thursday. The business’s 50 day moving average price is $0.97 and its 200-day moving average price is $2.09. Aldeyra Therapeutics has a 1 year low of $0.53 and a 1 year high of $5.93.
Insider Buying and Selling
In other news, Director Richard Douglas bought 200,000 shares of Aldeyra Therapeutics stock in a transaction on Wednesday, November 11th. The stock was acquired at an average price of $0.64 per share, with a total value of $128,000.00. Following the completion of the acquisition, the director directly owned 395,000 shares of the company’s stock, valued at $252,800. The trade was a 102.56% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 11.80% of the company’s stock.
Institutional Trading of Aldeyra Therapeutics
A number of institutional investors have recently made changes to their positions in ALDX. BlackRock Inc. purchased a new stake in shares of Aldeyra Therapeutics during the second quarter worth approximately $2,678,000. Renaissance Technologies LLC lifted its holdings in Aldeyra Therapeutics by 146.6% in the 1st quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock valued at $1,459,000 after purchasing an additional 513,187 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Aldeyra Therapeutics by 1.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 624,170 shares of the biotechnology company’s stock valued at $1,055,000 after purchasing an additional 11,912 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Aldeyra Therapeutics in the 2nd quarter valued at $1,007,000. Finally, Ieq Capital LLC purchased a new position in Aldeyra Therapeutics in the 2nd quarter valued at $440,000. 59.71% of the stock is owned by institutional investors and hedge funds.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases, including conditions affecting the eye. The company’s research centers on reactive aldehyde species (RASP), which it aims to inhibit to address inflammation and related disease processes. Aldeyra’s investigational medicines include reproxalap, a small-molecule RASP inhibitor studied for ocular conditions such as dry eye disease and allergic conjunctivitis. Its pipeline has also included candidates intended to treat systemic immune-mediated conditions.
Featured Articles
- Five stocks we like better than Aldeyra Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
